Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

about

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Item

http://www.wikidata.org/entity/Q50107743

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Incorporation of Urinary Prost ...... vention Trial Risk Calculator.

@en

Incorporation of Urinary Prost ...... vention Trial Risk Calculator.

@nl

type

Item

label

Incorporation of Urinary Prost ...... vention Trial Risk Calculator.

@en

Incorporation of Urinary Prost ...... vention Trial Risk Calculator.

@nl

prefLabel

Incorporation of Urinary Prost ...... vention Trial Risk Calculator.

@en

Incorporation of Urinary Prost ...... vention Trial Risk Calculator.

@nl

P1476

Incorporation of Urinary Prost ...... vention Trial Risk Calculator.

@en

P2093

Dattatraya Patil

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

John T Wei

http://www.w3.org/2001/XMLSchema#string

Jonathan Gelfond

http://www.w3.org/2001/XMLSchema#string

Martin G Sanda

http://www.w3.org/2001/XMLSchema#string

Martin Goros

http://www.w3.org/2001/XMLSchema#string

Michael A Liss

http://www.w3.org/2001/XMLSchema#string

Robin J Leach

http://www.w3.org/2001/XMLSchema#string

Scott A Tomlins

http://www.w3.org/2001/XMLSchema#string

Ziding Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan.

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.

Updating risk prediction tools: a case study in prostate cancer.

Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making.

P31

scholarly article

P356

10.1016/J.EUF.2018.01.010

http://www.w3.org/2001/XMLSchema#string

P50

Donna Ankerst

P577

2018-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29422418

http://www.w3.org/2001/XMLSchema#string

P932

6077104

http://www.w3.org/2001/XMLSchema#string